European thyroid journal · 2026
Real-world efficacy of lenvatinib/pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Talpacci Edoardo, Macera Manuela, Maida Giulia, Morelli Silvia, Leone Vincenzo, Ingriccini Chiara, Ferrieri Antonella, Tortoriello Rachele, Paci Miriam, Baldoni Monia, Morelli Olivia, Barp Samuele, Sponziello Marialuisa, Maranghi Marianna, Durante Cosimo, Grani Giorgio, Puxeddu Efisio
Аннотация
OBJECTIVE: Anaplastic thyroid carcinoma (ATC) is an extremely aggressive cancer, traditionally refractory to conventional treatments. The combined therapy with lenvatinib and pembrolizumab (L + P) is supported by a preclinical rationale based on the distinctive immunological profile of ATC. We propose a real-life study to evaluate relevant clinical outcomes and identify survival predictors in a cohort of ATC patients treated with the combined therapy in two Italian referral centers.
METHODS: Sixteen ATC patients treated with the combination of L + P were retrospectively included. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were assessed according to RECIST 1.1 criteria. Baseline patient characteristics, including immuno-nutritional status (calculated using the CONUT score), were analyzed to identify potential predictors of response.
RESULTS: A median OS of 10 months (95% CI: 4.2-15.9 months) and a median PFS of 6.0 months (95% CI: 0-12.7 months) were observed after L + P therapy. Complete response was observed in 6.2% and partial response in 31.3% of patients, resulting in an ORR of 37.5%; the DCR was 68.8%. Progressive disease occurred in 25% of patients. Furthermore, a baseline CONUT score ≤ 2 resulted in a significantly longer OS (log-rank, P = 0.001) and PFS (P = 0.05) compared to CONUT score ≥ 3, while a non-significantly longer OS was observed between patients with a baseline ECOG PS of 0-2 and those with a baseline ECOG PS ≥ 3.
CONCLUSION: Our study confirms the efficacy and safety of L + P therapy, identifying the CONUT score as a prognostic factor.
METHODS: Sixteen ATC patients treated with the combination of L + P were retrospectively included. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were assessed according to RECIST 1.1 criteria. Baseline patient characteristics, including immuno-nutritional status (calculated using the CONUT score), were analyzed to identify potential predictors of response.
RESULTS: A median OS of 10 months (95% CI: 4.2-15.9 months) and a median PFS of 6.0 months (95% CI: 0-12.7 months) were observed after L + P therapy. Complete response was observed in 6.2% and partial response in 31.3% of patients, resulting in an ORR of 37.5%; the DCR was 68.8%. Progressive disease occurred in 25% of patients. Furthermore, a baseline CONUT score ≤ 2 resulted in a significantly longer OS (log-rank, P = 0.001) and PFS (P = 0.05) compared to CONUT score ≥ 3, while a non-significantly longer OS was observed between patients with a baseline ECOG PS of 0-2 and those with a baseline ECOG PS ≥ 3.
CONCLUSION: Our study confirms the efficacy and safety of L + P therapy, identifying the CONUT score as a prognostic factor.